The acquisition of PONM gives Nexalin ownership of the AI-integrated software supporting its HALO Clarity program, preparing for a 160-participant trial for moderate-to-severe insomnia.
Key takeaways:
- Nexalin acquired PONM, securing exclusive rights to the digital health platform supporting its HALO Clarity program and Nexalin NeuroCare virtual clinic.
- The AI-integrated software offers remote patient monitoring, treatment-compliance data capture, and virtual-clinic management.
- The technology is currently deployed at the University of California, San Diego, and is being prepared for a 160-participant FDA pivotal trial of HALO Clarity for moderate-to-severe insomnia starting in Q2 2026.
- GreenLight Ventures, the former owner of PONM, enters a strategic partnership with Nexalin and becomes an equity holder.
Nexalin Technology Inc has closed its acquisition of PONM Inc from GreenLight Ventures LLC, securing the digital health platform that supports its HALO Clarity program and Nexalin NeuroCare virtual clinic.
Through the transaction, Nexalin gains ownership of PONM and an exclusive license to proprietary software features developed for the HALO program. This includes artificial intelligence (AI)-integrated remote patient monitoring, treatment-compliance data capture, electronic health record functionality, virtual-clinic management, and real-time clinical-data analysis.
The technology is currently deployed at the University of California, San Diego (UCSD), where it supports HALO headset usage tracking, remote prescribing, and physician oversight. At UCSD, phases one through five of the Nexalin NeuroCare virtual clinic have been deployed to support patient recruitment and clinical-data workflows for a military study, and are now being readied to support Nexalin’s planned 160-participant US Food and Drug Administration (FDA) pivotal trial of HALO Clarity for moderate-to-severe insomnia. Enrollment is expected to begin in the second quarter of 2026.
“This acquisition gives Nexalin ownership of a critical part of the HALO Clarity ecosystem: the digital platform that connects the device, the patient, the physician, and the clinical-data workflow,” says Mark White, CEO of Nexalin Technology, in a release. “The PONM platform is already deployed at UCSD and supports the AI-integrated remote-monitoring, clinical-data capture, and virtual-clinic capabilities we believe are essential to scaling HALO Clarity. By bringing this infrastructure under Nexalin ownership, we are strengthening our ability to execute through pivotal trial activities, planned FDA submission, and potential commercial launch.”
Nexalin notes this integrated device-plus-software model is important to its future regulatory strategy and potential commercial deployment of HALO Clarity as an at-home, physician-supervised therapy.
“We believe the future of neurostimulation will be defined not only by the device itself, but by the software, data, and physician-supervised care model around it,” says White in a release. “This transaction strengthens Nexalin’s control over that full ecosystem and expands what we believe the Company can ultimately offer to patients and providers seeking non-invasive treatment alternatives.”
Total consideration for the transaction is $1.3 million, payable in shares of Nexalin common stock. In connection with the transaction, GreenLight becomes a meaningful equity holder in Nexalin.
The two companies have also entered into a strategic partnership, providing Nexalin with continued access to GreenLight’s product, engineering, quality assurance, cybersecurity, regulatory, behavioral-health, and commercial-development capabilities.
“GreenLight has spent years building digital infrastructure for next-generation healthcare technologies, and HALO Clarity is exactly the type of platform our work was designed to support,” says Peter Gratale, founder of GreenLight Ventures, in a release. “With this transaction, Nexalin has the exclusive rights to the platform, while GreenLight remains aligned as both a long-term partner and shareholder.”
